IGFBP‑4 expression is adversely associated with lung cancer prognosis

Xiao,Yang; Zhu,Shan; Yin,Wen; Liu,Xiaofan; Hu,Yi

doi:10.3892/ol.2017.7014

IGFBP‑4 expression is adversely associated with lung cancer prognosis

Authors:
- Yang Xiao
- Shan Zhu
- Wen Yin
- Xiaofan Liu
- Yi Hu
View Affiliations

Affiliations: Department of Respiratory Medicine, Central Hospital of Wuhan, Wuhan, Hubei 430014, P.R. China
Published online on: September 21, 2017 https://doi.org/10.3892/ol.2017.7014
Pages: 6876-6880

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin‑like growth factor binding protein‑4 (IGFBP‑4) was reported to be associated with prognosis in several types of cancer; however, to the best of our knowledge, whether it is correlated with lung cancer has yet to be reported. In the present study, 102 pairs of lung cancer tissues and surrounding non‑cancerous tissues (SNCTs) were collected. The IGFBP‑4 levels in tissues were detected with immunohistochemistry. The relevance of IGFBP‑4 to the survival of patients was assessed. The IGFBP‑4 gene was knocked down, and its function in the proliferation of lung cancer cells was measured. The percentage of lung cancer tissues with higher IGFBP‑4 expression than SNCTs (51.9%) was increased compared with the percentage with similar (11.76%) or lower (36.27%) IGFBP‑4 expression. Patients with higher IGFBP‑1 expression exhibited a shorter median survival time. IGFBP‑1 was associated with metastasis, lung cancer stages and malignancy, but not with age, sex or tumor size. Lung cancer cells with stably knocked down IGFBP‑4 showed an inhibitory proliferation rate. The present study identified that IGFBP‑4 was adversely associated with the prognosis of lung cancer patients. IGFBP‑4 knockdown prohibited lung cancer cell growth. The present study provides a potential marker for lung cancer diagnosis and a possible target for lung cancer therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Rabasseda X: A report from the world conference on lung cancer (September 6–9, 2015-Denver, Colorado, USA). Drugs Today (Barc). 51:559–567. 2015.PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Shimasaki S, Shimonaka M, Zhang HP and Ling N: Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem. 266:10646–10653. 1991.PubMed/NCBI
5	Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K and Baylink DJ: Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 270:20424–20431. 1995. View Article : Google Scholar : PubMed/NCBI
6	Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, et al: IGFBP-4 is a candidate serum biomarker for detection and surveillance of early stage epithelial ovarian cancer. Research. 2:13422015. View Article : Google Scholar
7	Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, et al: IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. J Ovarian Res. 5:32012. View Article : Google Scholar : PubMed/NCBI
8	Drivdahl RH, Sprenger C, Trimm K and Plymate SR: Inhibition of growth and increased expression of insulin-like growth factor-binding protein-3 (IGFBP-3) and-6 in prostate cancer cells stably transfected with antisense IGFBP-4 complementary deoxyribonucleic acid. Endocrinology. 142:1990–1998. 2001. View Article : Google Scholar : PubMed/NCBI
9	Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lu W and Li Y: Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 115:1799–1807. 2014. View Article : Google Scholar : PubMed/NCBI
11	Al Dhaheri Y, Attoub S, Arafat K, Abuqamar S, Eid A, Al Faresi N and Iratni R: Salinomycin induces apoptosis and senescence in breast cancer: Upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochim Biophys Acta. 1830:3121–3135. 2013. View Article : Google Scholar : PubMed/NCBI
12	Fitzgibbons PL, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, Haas TS, Karabakhtsian RG, Loykasek PA, Marolt MJ, et al: Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 138:1432–1443. 2014. View Article : Google Scholar : PubMed/NCBI
13	Mellors RC: The application of labeled antibody technics in studying cell antigens. Cancer Res. 28:1372–1381. 1968.PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Durai R, Davies M, Yang W, Yang SY, Seifalian A, Goldspink G and Winslet M: Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol. 28:1317–1325. 2006.PubMed/NCBI
16	Diehl D, Lahm H, Wolf E and Bauersachs S: Transcriptome analysis of a human colorectal cancer cell line shows molecular targets of insulin-like growth factor-binding protein-4 overexpression. Int J Cancer. 113:588–599. 2005. View Article : Google Scholar : PubMed/NCBI
17	Resham K, Patel PN, Thummuri D, Guntuku L, Shah V, Bambal RB and Naidu VG: Preclinical drug metabolism and pharmacokinetics of salinomycin, a potential candidate for targeting human cancer stem cells. Chem Biol Interact. 240:146–152. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E and Roidl A: Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. 13:162014. View Article : Google Scholar : PubMed/NCBI
19	Naujokat C and Steinhart R: Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012:9506582012. View Article : Google Scholar : PubMed/NCBI
20	Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T and Wang J: Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 311:113–121. 2011. View Article : Google Scholar : PubMed/NCBI
21	Patel N, Baranwal S and Patel BB: A strategic approach to identification of selective inhibitors of cancer stem cells. Methods Mol Biol. 1229:529–541. 2015. View Article : Google Scholar : PubMed/NCBI
22	Győrffy B, Surowiak P, Budczies J and Lánczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
23	Uhlen M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
24	Ponten F, Jirström K and Uhlen M: The human protein Atlas-a tool for pathology. J Pathol. 216:387–393. 2008. View Article : Google Scholar : PubMed/NCBI
25	Yang Y, Xu H, Huang W, Ding M, Xiao J, Yang D, Li H, Liu XY and Chu L: Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med. 19:915–923. 2015. View Article : Google Scholar : PubMed/NCBI
26	Chen K, Huang YH and Chen JL: Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta Pharmacol Sin. 34:732–740. 2013. View Article : Google Scholar : PubMed/NCBI
27	Pine SR, Marshall B and Varticovski L: Lung cancer stem cells. Dis Markers. 24:257–266. 2008. View Article : Google Scholar : PubMed/NCBI